Weiwei Cheng

Weiwei Cheng

Auto-generated profile, based on publicly available information

Weiwei Cheng

Department of Nuclear Medicine, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 May 2021 in BMC Cancer
Verified
Journal Article
Open access
PDF file
XMXiaoran Mei
Xiaoran Mei
XYXiaoqin Yao
Xiaoqin Yao
FFFang Feng
Fang Feng
WCWeiwei Cheng
Weiwei Cheng
HWHui Wang
Hui Wang
Background: We identified differentiated thyroid cancer (DTC) survivors from SEER registries and performed Poisson regression to calculate the relative risks (RRs) of subsequent malignancies (SMs) by different sites associated with radioactive iodine (RAI) treatment, and the attributable risk proportion of RAI for developing different SMs. Results: We identified 4628 of 104,026 DTC patients developing a SM after two years of their DTC diagnosis, with a medium follow-up time of 113 months. The adjusted RRs of developing SM associated with RAI varied from 0.98 (0.58–1.65) for neurologic SMs to 1.37 (1.13–1.66) for hematologic SMs. The RRs of developing all cancer combined SMs generally increased with age at DTC diagnosis and decreased with the latency time. We estimated that the attributable risk proportion of RAI treatment is only 0.9% for all cancer combined SMs and 20% for hematologic SMs, which is the highest among all SMs. The tumor features and mortalities in patients treated with and without RAI are generally comparable. Conclusion: With the large population based analyses, we concluded that a low percentage of DTC survivors would develop SMs during their follow-up. Although the adjusted RR of SMs development increased slightly in patients receiving RAI, the attributable risk proportion associated with RAI was low, suggesting the absolute number of SMs induced by RAI in DTC survivors would be low. The attributable risk proportion of RAI treatment is the highest in hematological SMs, but when in consideration of its low incidence among all DTC survivors, the absolute number of hematological SMs was low.

6 June 2025 in Neurotherapeutics
Verified
Journal Article
Open access
HSHui Sun
Hui Sun
SGShenrui Guo
Shenrui Guo
HJHongfu Jin
Hongfu Jin
LDLin Ding
Lin Ding
YCYuanyuan Chen
Yuanyuan Chen
WCWeiwei Cheng
Weiwei Cheng
Cerebral glucose hypometabolism has been consistently associated with Alzheimer's disease (AD). With extensive efforts to eliminate AD pathologies, including the removal of amyloid-β ​(Aβ) plaques and hyperphosphorylated Tau, strategies aimed at restoring glucose metabolism in the brain regions most affected by AD are believed to have significant clinical implications. In this study, we demonstrated that glucose hypometabolism preceded neuronal death in triple-transgenic AD (3xTg-AD) mice, likely attributable to reduced expression of glucose transporter type 1 (GLUT1) or glucose transporter type 3 (GLUT3). Furthermore, we observed aberrant activation of the integrated stress response (ISR) pathway in AD models, with Aβ and Tau phosphorylation contributing to the activation of the ISR and subsequent reduction in GLUT1/3 expression. Inhibiting ISR activation by utilizing the ISR inhibitor ISRIB can effectively restore GLUT1/3 expression in both in vitro and in vivo models. Importantly, ISRIB treatment improved cognitive function and brain glucose metabolism in 3xTg-AD mice. Our findings suggest that targeting the ISR pathway to restore GLUTs expression may be a potential therapeutic strategy for AD.

17 May 2024 in European Radiology
Verified
Journal Article
Closed access
PDF file
XLXueyuan Lu
Xueyuan Lu
CLChao Li
Chao Li
SWShaoyan Wang
Shaoyan Wang
YYYafu Yin
Yafu Yin
HFHongliang Fu
Hongliang Fu
SCSuyun Chen
Suyun Chen

10 June 2023 in Molecular and Cellular Endocrinology
Verified
Journal Article
Closed access
ZXZhongyun Xu
Zhongyun Xu
YFYiyuan Feng
Yiyuan Feng
YYYeqing Yan
Yeqing Yan
HJHongfu Jin
Hongfu Jin
YCYuanyuan Chen
Yuanyuan Chen
WCWeiwei Cheng
Weiwei Cheng

10 March 2026 in EMBO Molecular Medicine
Verified
Journal Article
Open access
PDF file
SGShenrui Guo
Shenrui Guo
HJHongfu Jin
Hongfu Jin
HSHui Sun
Hui Sun
SHShuo Huang
Shuo Huang
YCYuanyuan Chen
Yuanyuan Chen
WCWeiwei Cheng
Weiwei Cheng
Pathological TAR DNA-binding protein-43 (TDP-43) is a defining feature of several neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD) and Alzheimer’s disease (AD). However, the mechanism by which TDP-43 pathology disrupts microglial function and drives neuroinflammation remains unclear. In this study, we demonstrated that cytoplasmically mis-localized TDP-43 exacerbated neuroinflammation, induced cell death, and impaired phagocytic function in microglial cells, primarily through receptor interacting serine/threonine kinase 3 (RIPK3)-dependent necroptosis. Pharmacological inhibition of RIPK3 with GSK872 markedly attenuated these pathological effects in vitro. These findings were further corroborated in a murine model with cytoplasmic TDP-43 mis-localization, where GSK872 treatment remarkably alleviated neuroinflammation and restored cognitive deficits. Mechanistically, our findings indicate that the nuclear depletion of TDP-43, resulted from its cytoplasmic mis-localization, impairs its ability to transcriptionally repress the Ripk3 gene, subsequently leading to RIPK3 upregulation and activation of RIPK3-dependent necroptosis. Collectively, our findings establish RIPK3-dependent necroptosis as a critical driver of TDP-43 pathology-mediated neuroinflammation and identified necroptosis as a promising therapeutic target in TDP-43-associated neurodegenerative disorders.